{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:51:02Z","timestamp":1767999062605,"version":"3.49.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>Hyperhemolysis is a life-threatening condition of exaggerated hemolysis of red blood cells which occurs in patients receiving chronic transfusion therapy. We present a 19-year-old male with the \u03b2-thalassemia major with an episode of hyperhemolysis. Hemolysis was initially unresponsive to immunosuppression but responded after the addition of eculizumab. Several weeks after stabilization, hemolysis returned; which was also managed with immunosuppression and eculizumab. Hyperhemolysis presents significant challenges in \u03b2-thalassemia due to the underlying dysfunctional erythropoiesis and transfusion dependence. Aggressive immunosuppression combined with eculizumab successfully slowed the hemolysis and allowed for the resumption of transfusions.<\/jats:p>","DOI":"10.1097\/mph.0000000000002059","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T16:16:33Z","timestamp":1611418593000},"page":"e1145-e1147","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Management of Hyperhemolysis in \u03b2-thalassemia With Multiple Immunosuppressives, Including Complement Blockade"],"prefix":"10.1097","volume":"43","author":[{"given":"Richard C.","family":"Zanetti","sequence":"first","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"Vasta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"},{"name":"National Capital Consortium, Walter Reed National Military Medical Center, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Romanelli","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"},{"name":"National Capital Consortium, Walter Reed National Military Medical Center, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Newton","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders, Pediatric Specialists of Virginia, Fairfax, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tmrv.2015.06.001","article-title":"Hyperhemolysis in patients with hemoglobinopathies: a single-center experience and review of the literature","volume":"29","author":"Danaee","year":"2015","journal-title":"Transfus Med Rev"},{"key":"R2-20250804","first-page":"305","article-title":"An animal model for delayed hemolytic transfusion reactions","volume":"15","author":"Ness","year":"2001","journal-title":"Transfus Med Rev"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.tmrv.2019.09.007","article-title":"The role of complement in post-transfusion hemolysis and hyperhemolysis reaction","volume":"33","author":"Roumenina","year":"2019","journal-title":"Transfus Med Rev"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/trf.13144","article-title":"Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab","volume":"55","author":"Boonyasampant","year":"2015","journal-title":"Transfusion"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2015-09-669770","article-title":"Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients","volume":"127","author":"Dumas","year":"2016","journal-title":"Blood"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/trf.15198","article-title":"Anti-N and anti-Do(a) immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature","volume":"59","author":"Unnikrishnan","year":"2019","journal-title":"Transfusion"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/03630269.2018.1540353","article-title":"Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement inhibition","volume":"42","author":"Vlachaki","year":"2018","journal-title":"Hemoglobin"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.3324\/haematol.2018.194670","article-title":"Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease","volume":"103","author":"Chonat","year":"2018","journal-title":"Haematologica"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/trf.12876","article-title":"Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab","volume":"55","author":"Gupta","year":"2015","journal-title":"Transfusion"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1111\/trf.15445","article-title":"A case-control analysis of hyperhemolysis syndrome in adults and laboratory correlates of complement involvement","volume":"59","author":"Merrill","year":"2019","journal-title":"Transfusion"},{"key":"R11-20250804","first-page":"205","article-title":"Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents","volume":"2","author":"Risitano","year":"2008","journal-title":"Biologics"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5114\/aoms.2018.81036","article-title":"The effect of splenectomy on complement regulatory proteins in erythrocytes in beta-thalassemia major","volume":"15","author":"Kurtogllu","year":"2019","journal-title":"Arch Med Sci"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T21:00:49Z","timestamp":1754341249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002059","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"2020-10-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}